Pediatric Leukemia



Alternative Splicing and Leukemia Initiating Cells


Condition:   Acute Myeloid Leukemia
Intervention:   Other: Assessment of splicing variants
Sponsor:   Hospices Civils de Lyon
Recruiting - verified April 2017


Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy


Condition:   Acute Promyelocytic Leukemia
Intervention:   Other: QoL questionnaires
Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified May 2017


Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)


Condition:   Acute Promyelocytic Leukemia
Interventions:   Drug: Realgar-Indigo naturalis formula;   Drug: all-trans retinoic acid;   Drug: Arsenic trioxide;   Drug: Hydroxyurea
Sponsors:   First Affiliated Hospital Xi'an Jiaotong University;   Tang-Du Hospital
Recruiting - verified August 2016


Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia


Condition:   Leukemia
Intervention:   Biological: CD19-targeted CAR-T cells
Sponsors:   Sinobioway Cell Therapy Co., Ltd.;   The Second Hospital of Anhui Medical University
Recruiting - verified November 2016


Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia


Condition:   Acute Promyelocytic Leukemia
Interventions:   Drug: Arsenic trioxide;   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Tretinoin;   Drug: Mitoxantrone;   Drug: Mercaptopurine;   Drug: Methotrexate
Sponsors:   Technische Universität Dresden;   Gruppo Italiano Malattie EMatologiche dell'Adulto;   Groupe Francophone des Myelodysplasies;   Haemato Oncology Foundation for Adults in the Netherlands;   Programa para el Tratamiento de Hemopatías Malignas;   German Federal Ministry of Education and Research;   Teva Pharmaceuticals Europe
Recruiting - verified July 2016


Samples From Leukemia Patients and Their Donors to Identify Specific Antigens


Condition:   Leukemia
Intervention:  
Sponsor:   University of California, San Diego
Recruiting - verified May 2017


Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children


Condition:   Leukemia
Interventions:   Drug: Bortezomib;   Drug: Pravastatin
Sponsors:   Reuven Schore;   Millennium Pharmaceuticals, Inc.;   Hyundai Hope On Wheels
Recruiting - verified February 2017


Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia


Condition:   Leukemia
Interventions:   Drug: BAY1143572;   Drug: BAY1143572
Sponsor:   Bayer
Active, not recruiting - verified May 2017


A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia


Conditions:   Chronic Lymphocytic Leukemia;   Leukemia
Interventions:   Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
Sponsors:   Dana-Farber Cancer Institute;   Pharmacyclics LLC.
Recruiting - verified April 2017


Comparison of Laboratory Test Results of Minimal-Residual Disease in Samples From Patients With Acute Myeloid Leukemia


Condition:   Leukemia
Interventions:   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Completed - verified July 2016


Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin


Condition:   Leukemia
Interventions:   Drug: ATRA;   Drug: ATO;   Drug: GO (Gemtuzumab ozogamicin);   Drug: Methylprednisolone
Sponsors:   M.D. Anderson Cancer Center;   Pfizer
Recruiting - verified September 2016


Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia


Condition:   Leukemia
Interventions:   Genetic: DNA analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Active, not recruiting - verified July 2016


Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia


Condition:   Leukemia
Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Active, not recruiting - verified July 2016


Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia


Condition:   Leukemia
Interventions:   Genetic: microarray analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: flow cytometry
Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
Completed - verified May 2017


JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia


Condition:   Leukemia
Interventions:   Drug: JVRS-100;   Drug: JVRS-100
Sponsor:   Milton S. Hershey Medical Center
Active, not recruiting - verified January 2017


A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib


Condition:   Leukemia
Intervention:   Drug: Dasatinib
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified October 2016


S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia


Condition:   Leukemia
Interventions:   Drug: arsenic trioxide;   Drug: gemtuzumab ozogamicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Active, not recruiting - verified October 2016


Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia


Condition:   Leukemia
Interventions:   Biological: rituximab;   Drug: fludarabine phosphate
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Active, not recruiting - verified July 2016


Phase III Trial in Acute Promyelocytic Leukemia Patients


Condition:   Leukemia
Interventions:   Drug: arsenic trioxide;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: all-trans retinoic acid;   Drug: all-trans retinoic acid (ATRA)
Sponsors:   Gruppo Italiano Malattie EMatologiche dell'Adulto;   Study Alliance Leukemia (SAL) Group
Active, not recruiting - verified February 2017


Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia


Condition:   Leukemia
Interventions:   Drug: Dasatinib;   Drug: Dasatinib;   Drug: Dasatinib
Sponsors:   Bristol-Myers Squibb;   Innovative Therapies For Children with Cancer Consortium
Active, not recruiting - verified December 2016


Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia


Condition:   Leukemia
Interventions:   Biological: rituximab;   Drug: lenalidomide
Sponsors:   Roswell Park Cancer Institute;   Celgene
Completed - verified July 2016


Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia


Condition:   Leukemia
Intervention:   Biological: denileukin diftitox
Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
Completed - verified June 2013


Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia


Condition:   Leukemia
Intervention:   Drug: gemcitabine hydrochloride
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed - verified December 2016


Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia


Condition:   Leukemia
Interventions:   Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: fludarabine phosphate
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
Completed - verified January 2017


DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia


Condition:   Leukemia
Intervention:   Biological: DTGM fusion protein
Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
Completed - verified June 2013

Refine Your Search Advanced Search